Last reviewed · How we verify

L-Tryptophan (TRYPTOPHAN)

FDA-approved withdrawn Small molecule

L-Tryptophan works by inhibiting the enzyme myeloperoxidase, which is involved in producing reactive oxygen species.

L-Tryptophan is a small molecule tryptophan drug that targets myeloperoxidase. It is not FDA approved for any indications, and its commercial status is unknown. As a tryptophan, it is involved in various biological processes, including protein synthesis and neurotransmitter production. L-Tryptophan's mechanism of action involves inhibiting myeloperoxidase, an enzyme involved in the production of reactive oxygen species. Further information on its clinical use and safety profile is not available.

At a glance

Generic nameTRYPTOPHAN
Drug classtryptophan
TargetMyeloperoxidase, Extracellular calcium-sensing receptor, Probable G-protein coupled receptor 139
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Mechanism of action

CLINIMIX is used as supplement of nutrition in patients, providing macronutrients (amino acids and dextrose) parenterally.The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as source of energy.The administered dextrose is oxidized to carbon dioxide and water, yielding energy.

Approved indications

No approved indications tracked.

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: